Purpose and Summary
Introduced on February 17, 2023, by Representative Monica
De La Cruz, H.R. 1076, the Preventing the Financing of Illegal
Synthetic Drugs Act, instructs the Comptroller General of the
United States to carry out a study on illicit financing in
connection with the trafficking of synthetic drugs and related
illicit finance. Without financing, a business cannot operate.
The study will provide policymakers with better information on
how traffickers operate and facilitate illicit activity to
draft effective legislation.
Background and Need for Legislation
According to the Center for Disease Control, over 107,000
people in the United States died from drug overdoses or drug
poisons in 2022.\1\ Sixty-seven percent of those deaths
involved synthetic opioids like fentanyl. Financing is
essential to support and sustain the logistics needed to carry
out large and small-scale trafficking operations. A detailed
study examining the business model of synthetic trafficking,
the ways in which the business model overlaps with human
trafficking, and the use of online illicit drug markets and
financial methods used to carry out illicit activity will allow
policymakers to better prioritize U.S. government activities to
combat the illicit finance related to the trafficking of
synthetic drugs.
---------------------------------------------------------------------------
\1\https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/
202205.htm.
---------------------------------------------------------------------------
HEARING
The Committee on Financial Services held a hearing
examining matters relating to H.R. 1076 on February 7, 2023.
Committee Consideration
The Committee on Financial Services met in open session on
February 28, 2023, and ordered H.R. 1076 to be reported
favorably to the House as amended by voice vote, a quorum being
present. Before the question to report was called, the
Committee adopted an amendment in the nature of a substitute
offered by Ms. De La Cruz by voice vote.
Committee Votes
Clause 2(b) of rule XIII of the Rules of the House of
Representatives requires the Committee to list the record votes
on the order to report legislation and amendments thereto. H.R.
1076 was reported favorably to the House as amended by voice
vote, a quorum being present.
COMMITTEE OVERSIGHT FINDINGS
Pursuant to clause 3(c) of rule XIII of the Rules of the
House of Representatives, the findings and recommendations of
the Committee based on oversight activities under clause
2(b)(1) of rule X of the Rules of the House of Representatives,
are incorporated in the descriptive portions of this report.
PERFORMANCE GOALS AND OBJECTIVES
Pursuant to clause 3(c)(4) of rule XIII of the Rules of the
House of Representatives, the goal of H.R. 1076 is to provide
lawmakers with better information on how traffickers operate
and facilitate illicit activity to draft effective legislation
through a study, conducted by the Comptroller General of the
United States, on illicit financing in connection with the
trafficking of synthetic drugs and related illicit finance.
NEW BUDGET AUTHORITY, ENTITLEMENT AUTHORITY, AND TAX EXPENDITURES
In compliance with clause 3(c)(2) of rule XIII of the Rules
of the House of Representatives, the Committee adopts as its
own the estimate of new budget authority, entitlement
authority, or tax expenditures or revenues contained in the
cost estimate prepared by the Director of the Congressional
Budget Office pursuant to section 402 of the Congressional
Budget Act of 1973.
CONGRESSIONAL BUDGET OFFICE ESTIMATES
Pursuant to clause 3(c)(3) of rule XIII of the Rules of the
House of Representatives, the following is the cost estimate
provided by the Congressional Budget Office pursuant to section
402 of the Congressional Budget Act of 1974:
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
H.R. 1076 would require the Government Accountability
Office (GAO) to study the illicit financing of synthetic-drug
trafficking and the federal government's efforts to combat
those activities. The bill would require the GAO to report its
findings to the Congress within one year of enactment.
Based on the cost to produce similar reports, CBO estimates
that implementing H.R. 1076 would cost less than $500,000 over
the 2023-2028 period; any such spending would be subject to the
availability of appropriated funds.
The CBO staff contact for this estimate is Jeremy Crimm.
The estimate was reviewed by Chad Chirico, Deputy Director of
Budget Analysis.
Phillip L. Swagel,
Director, Congressional Budget Office.
FEDERAL MANDATES STATEMENT
This information is provided in accordance with section 423
of the Unfunded Mandates Reform Act of 1995.
The Committee has determined that the bill does not contain
Federal mandates on the private sector. The Committee has
determined that the bill does not impose a Federal
intergovernmental mandate on State, local, or tribal
governments.
ADVISORY COMMITTEE STATEMENT
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
APPLICABILITY TO LEGISLATIVE BRANCH
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of the section
102(b)(3) of the Congressional Accountability Act.
EARMARK IDENTIFICATION
With respect to clause 9 of rule XIII of the Rules of the
House of Representatives, the Committee has carefully reviewed
the provisions of the bill and states that the provisions of
the bill do not contain any congressional earmarks, limited tax
benefits, or limited tariff benefits within the meaning of the
rule.
DUPLICATION OF FEDERAL PROGRAMS
In compliance with clause 3(c)(5) of rule XIII of the Rules
of the House of Representatives, the Committee states that no
provision of the bill establishes or reauthorizes: (1) a
program of the Federal Government known to be duplicative of
another Federal program; (2) a program included in any report
form the Government Accountability Office to Congress pursuant
to section 21 of Public Law 111-139; or (3) a program related
to a program identified in the most recent Catalog of Federal
Domestic Assistance, published pursuant to the Federal Program
Information Act (Pub. L. No. 85-220, as amended by Pub. L. No.
98-169).
SECTION-BY-SECTION ANALYSIS OF THE LEGISLATION
Sec. 1: Short title
This Act may be cited as the ``Preventing the Financing of
Illegal Synthetic Drugs Act''.
Sec. 2: Findings
This section sets out a series of findings describing the
financing of, trafficking in, and the pervasiveness use of
synthetic drugs, including fentanyl.
Sec. 3: GAO study on synthetic drugs trafficking
This section directs the Comptroller General of the United
States to carry out a study on illicit financing in connection
with the trafficking of synthetic drugs, including fentanyl.
CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED
H.R. 1076 does not repeal or amend any section of a
statute. Therefore, the Office of Legislative Counsel did not
prepare the report contemplated by clause 3(e)(1)(B) of rule
XIII of the House of Representatives.
[all]